Mackenzie Financial Corp grew its holdings in shares of Danaher Corporation (NYSE:DHR) by 6.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,861,730 shares of the conglomerate’s stock after purchasing an additional 111,326 shares during the period. Danaher makes up 0.9% of Mackenzie Financial Corp’s portfolio, making the stock its 25th biggest holding. Mackenzie Financial Corp owned 0.27% of Danaher worth $159,699,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. Harfst & Associates Inc. bought a new position in Danaher during the first quarter valued at approximately $205,000. Monroe Bank & Trust MI grew its holdings in Danaher by 0.6% during the first quarter. Monroe Bank & Trust MI now owns 13,723 shares of the conglomerate’s stock valued at $1,174,000 after purchasing an additional 77 shares during the last quarter. BlackRock Inc. grew its holdings in Danaher by 2,530.9% during the first quarter. BlackRock Inc. now owns 37,967,922 shares of the conglomerate’s stock valued at $3,247,398,000 after purchasing an additional 36,524,795 shares during the last quarter. Hamilton Point Investment Advisors LLC lifted its position in Danaher by 2.0% in the first quarter. Hamilton Point Investment Advisors LLC now owns 38,188 shares of the conglomerate’s stock worth $3,266,000 after purchasing an additional 735 shares during the period. Finally, KCG Holdings Inc. lifted its holdings in shares of Danaher by 88.3% during the first quarter. KCG Holdings Inc. now owns 14,483 shares of the conglomerate’s stock valued at $1,239,000 after acquiring an additional 6,793 shares during the period. 76.32% of the stock is owned by institutional investors.

Danaher Corporation (NYSE:DHR) traded down $0.21 during trading on Thursday, hitting $92.53. The stock had a trading volume of 2,038,300 shares, compared to its average volume of 2,630,318. The firm has a market cap of $64,510.42, a price-to-earnings ratio of 23.84, a P/E/G ratio of 2.21 and a beta of 1.02. Danaher Corporation has a 52 week low of $76.27 and a 52 week high of $94.82. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.00.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.05. Danaher had a return on equity of 11.29% and a net margin of 13.36%. The business had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.47 billion. During the same period in the previous year, the firm earned $0.87 EPS. Danaher’s quarterly revenue was up 9.6% compared to the same quarter last year. equities research analysts expect that Danaher Corporation will post 3.99 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be given a $0.14 dividend. The ex-dividend date is Thursday, December 28th. This represents a $0.56 annualized dividend and a dividend yield of 0.61%. Danaher’s dividend payout ratio is presently 16.52%.

In related news, CAO Robert S. Lutz sold 11,189 shares of the business’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $91.66, for a total value of $1,025,583.74. Following the completion of the transaction, the chief accounting officer now directly owns 18,314 shares in the company, valued at approximately $1,678,661.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Daniel L. Comas sold 88,184 shares of the business’s stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $91.02, for a total value of $8,026,507.68. Following the completion of the transaction, the chief financial officer now owns 227,816 shares of the company’s stock, valued at $20,735,812.32. The disclosure for this sale can be found here. Insiders sold a total of 273,810 shares of company stock valued at $25,218,813 over the last quarter. 12.20% of the stock is owned by insiders.

A number of brokerages recently commented on DHR. J P Morgan Chase & Co reiterated an “overweight” rating and issued a $95.00 price objective on shares of Danaher in a research report on Friday, September 8th. Goldman Sachs Group reiterated a “neutral” rating and issued a $83.00 price objective on shares of Danaher in a research report on Tuesday, September 26th. Cowen reiterated a “buy” rating and issued a $90.00 price objective on shares of Danaher in a research report on Wednesday, October 4th. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $97.00 price objective for the company in a research report on Thursday, October 5th. Finally, Morgan Stanley restated an “overweight” rating and set a $95.00 target price (up from $86.00) on shares of Danaher in a research report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Danaher presently has an average rating of “Buy” and an average target price of $93.31.

WARNING: “Mackenzie Financial Corp Boosts Stake in Danaher Corporation (DHR)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/12/07/mackenzie-financial-corp-boosts-stake-in-danaher-corporation-dhr.html.

About Danaher

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Stock Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related stocks with our FREE daily email newsletter.